An animal model of schizophrenia based on chronic LSD administration: Old idea, new results

Bortolozzi, 2010, Dopamine release induced by atypical antipsychotics in prefrontal cortex requires 5-HT1A receptors but not 5-HT2A receptors, Int. J. Neuropsychopharmacol., 1 Dall’Olio, 1999, The non-competitive NMDA receptor blocker dizocilpine potentiates serotonergic function, Behav. Pharmacol, 10, 63, 10.1097/00008877-199902000-00006 Arnt, 1996, Inhibitory effects on the discriminative stimulus properties of d-amphetamine by classical and newer antipsychotics do not correlate with antipsychotic activity. Relation to effects on the reward system?, Psychopharmacology, 124, 117, 10.1007/BF02245611 Bardgett, 2002, The effects of excitocic hippocampal lesions in rats on resperidone- and olanzapine-induced locomotor suppression, Neuropsychopharmacology, 27, 930, 10.1016/S0893-133X(02)00376-7 Bradford, 2010, Validation and pharmacological characterizataion of MK-801-induced locomotor hyperactivity in BALB/C mice as an assay for detection of novel antipsychotics, Psychopharmacology, 212, 155, 10.1007/s00213-010-1938-0 Castensson, 2003, Decrease of serotonin receptor 2C in schizophrenia brains identified by high-resolution mRNA expression analysis, Biol. Psychiatry, 54, 1212, 10.1016/S0006-3223(03)00526-2 Freedman, 1986, Hallucinogenic drug research -If so, so what?: symposium summary and commentary, Pharmacol. Biochem. Behav., 24, 407, 10.1016/0091-3057(86)90371-0 Frye, 2003, Olanzapine’s effects to reduce fear and anxiety and enhance social interactions coincide with increased progestin concentrations of ovariectomized rats, Psychoneuroendocrynology, 28, 657, 10.1016/S0306-4530(02)00049-5 Gordon, 2010, Testing the glutamate hypothesis of schizophrenia, Nat. Neurosci., 13, 2, 10.1038/nn0110-2 Hofmann, 1979, How LSD originated, J. Psychedelic Drugs, 11, 53, 10.1080/02791072.1979.10472092 Jones, 2008, Developing new drugs in schizophrenia: from animals to the clinic, Vol 1 Kim, 1999, NMDA receptor antagonists enhance 5-HT2 receptor-mediated behavior, head-twitch response, in PCPA-treated mice, Arch. Pharm.Res., 22, 113, 10.1007/BF02976533 Large, 2007, Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs?, J. Psychopharmacol., 21, 283, 10.1177/0269881107077712 Litchfield, 1949, A simplified method of evaluating dose-effect experiments, J. Pharmacol. Exp. Ther., 96, 99 Marona-Lewicka, 1994, Behavioral effects of the highly selective serotonin releasing agent 5-methoxy-6-methyl-2-aminoindan, Eur. J. Pharmacol., 258, 1, 10.1016/0014-2999(94)90051-5 Marona-Lewicka, 2007, Further evidence that the delayed temporal dopaminergic effects of LSD are mediated by a mechanism different than the first temporal phase of action, Pharmacol. Biochem. Behav., 87, 453, 10.1016/j.pbb.2007.06.001 Marona-Lewicka, 2005, Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis, Psychopharmacology (Berl), 180, 427, 10.1007/s00213-005-2183-9 Marona-Lewicka, 2008, Dopamine D(4) receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen DOI, Psychopharmacology (Berl), 203, 265, 10.1007/s00213-008-1238-0 Meil, 1997, Olanzapine attenuates the reinforcing effects of cocaine, Eur. J. Pharmacol., 340, 17, 10.1016/S0014-2999(97)01351-4 Moghaddam, 1997, Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex, J. Neurosci., 17, 2921, 10.1523/JNEUROSCI.17-08-02921.1997 Muschamp, 2004, Lysergic acid diethylamide and [-]-2,5-dimethoxy-4-methylamphetamine increase extracellular glutamate in rat prefrontal cortex, Brain Res., 1023, 134, 10.1016/j.brainres.2004.07.044 Nichols, 2004, Hallucinogens. Pharmacol. Ther., 101, 131, 10.1016/j.pharmthera.2003.11.002 Nichols, 2002, A single dose of lysergic acid diethylamide influences gene expression patterns within the mammalian brain, Neuropsychopharmacology, 26, 634, 10.1016/S0893-133X(01)00405-5 Nichols, 2004, Molecular genetic responses to lysergic acid diethylamide include transcriptional activation of MAP kinase phosphatase-1, C/EBP-beta and ILAD-1, a novel gene with homology to arrestins, J. Neurochem., 90, 576, 10.1111/j.1471-4159.2004.02515.x Nichols, 2003, Dynamic changes in prefrontal cortex gene expression following lysergic acid diethylamide administration, Brain Res. Mol. Brain Res., 111, 182, 10.1016/S0169-328X(03)00029-9 Passie, 1997 Takahata, 2003, Activation of glutamate neurotransmission in the prefrontal cortex sustains the motoric and dopaminergic effects of phencyclidine, Neuropsychopharmacology, 28, 1117, 10.1038/sj.npp.1300127 Tallerico, 2001, Schizophrenia: elevated mRNA for dopamine D2(Longer) receptors in frontal cortex, Brain Res. Mol. Brain Res., 87, 160, 10.1016/S0169-328X(00)00293-X van Elst, 2005, Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study, Biol. Psychiatry, 58, 724, 10.1016/j.biopsych.2005.04.041 Vollenweider, 2001, A systems model of altered consciousness: integrating natural and drug-induced psychoses, Brain Res. Bull., 56, 495, 10.1016/S0361-9230(01)00646-3 Wadenberg, 2001, Dopamine D2 receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects, Neuropsychopharmacology, 25, 633, 10.1016/S0893-133X(01)00261-5 Winter, 2000, Potentiation of DOM-induced stimulus control by non-competitive NMDA antagonists. A link between the glutamatergic and serotonergic hypothesis of schizophrenia, Life Sci., 68, 337, 10.1016/S0024-3205(00)00934-6 Winter, 2004, Serotonergic/glutamatergic interactions: the effects of mGlu2/3 receptor ligands in rats trained with LSD and PCP as discriminative stimuli, Psychopharmacology (Berl), 172, 233, 10.1007/s00213-003-1636-2 Zar, 1999